Department of Hematology & Oncology, Albert Ludwigs-University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany.
Biol Blood Marrow Transplant. 2012 Jun;18(6):894-902. doi: 10.1016/j.bbmt.2011.11.017. Epub 2011 Nov 20.
Peripheral blood stem cells (PBSCs) are increasingly used as the graft source in allogeneic hematopoietic cell transplantation. We compared long-term outcome after unrelated donor transplantation of 85 consecutive patients with acute myelogenous leukemia or myelodysplastic syndrome regarding disease status (early disease [CR1, refractory anemia); n = 25 and advanced/active disease [>CR1, >refractory anemia]; n = 60) who were treated with conventional conditioning regimens followed by bone marrow (BM) or PBSC grafts. Graft-versus-host disease prophylaxis consisted mainly of cyclosporine A, short-course methotrexate, and anti-T-lymphocyte globulin. After a median follow-up of 118 months (68-174), the 10-year event-free survival rate after peripheral blood stem cell transplantation (PBSCT) was 54.8% (95% confidence interval [CI], 39.7%-69.8%), and after bone marrow transplantation (BMT), it was 27.9% (14.5%-41.3%; P < .004). In the advanced/active disease group, the 10-year event-free survival rate after PBSCT was 50% (30.8%-69.2%), and after BMT, it was 23.5% (9.3%-37.8%; P < .007). Non relapse mortality was less after PBSCT than BMT (14.3% vs 30.2%), respectively. In multivariate Cox regression analysis, PBSCT showed a better overall survival (OS; hazard ratio [HR], 0.43; 95% CI, 0.23-0.79; P = .007) compared to BMT; unfavorable/unknown prognostic impact cytogenetic abnormalities were an adverse factor for all patients (HR, 2.202; 95% CI, 1.19-4.06; P = .011). In patients with advanced disease, the use of PBSCs showed a significant favorable outcome via multivariate analysis (HR, 0.49; 95% CI, 0.24-0.99; P = .046). Outcome of acute myelogenous leukemia/myelodysplastic syndrome after unrelated hematopoietic cell transplantation is adversely affected by cytogenetic abnormalities and state of remission at hematopoietic cell transplantation. PBSC as a graft source has a significant favorable influence on survival.
外周血造血干细胞(PBSCs)越来越多地被用作异基因造血细胞移植中的移植物来源。我们比较了 85 例连续接受急性髓系白血病或骨髓增生异常综合征治疗的患者的长期结果,这些患者的疾病状态不同(早期疾病[CR1,难治性贫血];n=25 和晚期/活动期疾病[>CR1,难治性贫血>;n=60),他们接受了常规的预处理方案,随后进行骨髓(BM)或 PBSC 移植。移植物抗宿主病的预防主要包括环孢素 A、短程甲氨蝶呤和抗淋巴细胞球蛋白。中位随访 118 个月(68-174 个月)后,外周血造血干细胞移植(PBSCT)后的 10 年无事件生存率为 54.8%(95%置信区间[CI],39.7%-69.8%),骨髓移植(BMT)后的 10 年无事件生存率为 27.9%(14.5%-41.3%;P<.004)。在晚期/活动期疾病组中,PBSCT 后 10 年无事件生存率为 50%(30.8%-69.2%),BMT 后为 23.5%(9.3%-37.8%;P<.007)。非复发死亡率在 PBSCT 后低于 BMT(分别为 14.3%和 30.2%)。在多变量 Cox 回归分析中,PBSCT 与 BMT 相比显示出更好的总体生存率(OS;风险比[HR],0.43;95%CI,0.23-0.79;P=0.007);不良/未知预后的细胞遗传学异常是所有患者的不利因素(HR,2.202;95%CI,1.19-4.06;P=0.011)。在晚期疾病患者中,通过多变量分析显示使用 PBSC 具有显著的有利结果(HR,0.49;95%CI,0.24-0.99;P=0.046)。异基因造血细胞移植后急性髓系白血病/骨髓增生异常综合征的结果受细胞遗传学异常和造血细胞移植时缓解状态的不利影响。作为移植物来源的 PBSC 对生存有显著的积极影响。